SmallCap Trading Techniques

[I Like Bottom Fishing]

HPLF News HepaLife(TM) Develops New Liver Stem Cell Lines fo...
Wednesday, June 25, 2008 9:17 AM

Scottrade.com
This email is compliments of Scottrade.com


News for 'HPLF' - (HepaLife(TM) Develops New Liver Stem Cell Lines for Bioartificial Liver Device; Data Presented at Scientific Conferences)


BOSTON, Jun 25, 2008 (BUSINESS WIRE) -- HepaLife Technologies, Inc. (OTCBB:
HPLF) (FWB: HL1) (WKN: 500625), today announced the development of two new
derivative cell lines from the Company's patented PICM-19 liver stem cells for
use in HepaLife's first-of-its-kind bioartificial liver device currently under
development for the treatment of human liver failure.

"These two cell lines have unique and special functionalities, and make it
possible to more closely model the function of the natural liver in our device
than before," explained Mr. Frank Menzler, President and CEO of HepaLife
Technologies, Inc. "These cell lines further enable us to progress more rapidly
in our efforts to scale-up the manufacturing into larger-scale production of our
cells, an important requirement for using the cells inside an artificial liver
device."

Researchers presented initial data on the Company's new cell lines at the 6th
Annual Meeting of International Society for Stem Cell Research in Philadelphia,
PA and the 54th American Society of Internal Artificial Organs annual conference
in San Francisco, CA, earlier this month.

The two immortalized unipotent porcine liver stem cell lines are: the
'PICM-19H', capable of differentiating exclusively into 'hepatocytes' or liver
cells with the ability to express hepatocyte or liver-cell function; and, the
'PICM-19B,' capable of differentiating exclusively into bile duct cells with the
ability to express bile duct cell function.

In ongoing tests, scientists have confirmed that HepaLife's PICM-19H cells
favorably differentiate into hepatocytes as evidenced by their 'morphology', or
form and structure. The PICM-19H also express the most important liver functions
key to replicating the human liver, expressing hepatocyte functions such as
Phase I (P450) and Phase II metabolic activity, serum protein synthesis, low
gamma-glutamyl transpeptidase (GGT) activity, ammonia clearance and urea
synthesis similar to primary adult cells. The cells have demonstrated the
ability to successfully retain the highest levels of liver-specific metabolic
activity over prolonged periods of time.

The PICM-19B cell line, which differentiates exclusively into functional bile
duct cells (cholangiocytes) show that the cells form confluent (complete) cell
monolayers in culture, are basolaterally polarized cells exhibiting basal
membrane fluid transport, have high GGT activity and have greatly reduced serum
protein production.

Intended for the treatment of liver failure, the HepaLife(TM) Bioartificial
Liver device consists of three basic components: (1) a plasma filter, separating
the patient's blood into blood plasma and blood cells; (2) the bioreactor, a
unit filled with the patented PICM-19 liver stem cell line which biologically
mimics the liver's function; and (3), the HepaDrive(TM), a perfusion system for
pumping the patient's plasma through the bioreactor while controlling gas supply
and temperature for best possible performance of the cells.

ABOUT HEPALIFE TECHNOLOGIES, INC.

Based in Boston, Massachusetts, HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB:
HL1) (WKN: 500625) is a developer of cell-based medical technologies addressing
prevalent human health concerns.

HepaLife is developing the first-of-its-kind bioartificial liver device intended
for the treatment of liver failure using the Company's patented PICM-19 liver
stem cell line. The HepaLife(TM) bioartificial liver, currently under
development, is designed to serve as a supportive device, either allowing the
liver to regenerate upon acute liver failure, or to bridge the patient's liver
functions until a transplant is available.

Utilizing its patented liver stem cell line PICM-19, HepaLife is designing
testing platforms to improve the pharmaceutical industry's capability to
evaluate drug toxicity and possible side-effects before pharmaceutical compounds
are commercially distributed.

Any statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:
http://www.hepalife.com/investor_alerts.php

To view the full HTML text of this release, please visit:
http://www.hepalife.com/press_releases/20080625.html.php

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer
for the purchase or sale of any securities. This release contains
forward-looking statements that are based upon current expectations or beliefs,
as well as a number of assumptions about future events. Although the Company
believes that the expectations reflected in the forward-looking statements and
the assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have been
correct. Forward-looking statements, which involve assumptions and describe our
future plans, strategies, and expectations, are generally identifiable by use of
the words "may," "will," "should," "could," "expect," "anticipate," "estimate,"
"believe," "intend," or "project" or the negative of these words or other
variations on these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these statements
are subject to numerous factors and uncertainties, including but not limited to
adverse economic conditions, intense competition, lack of meaningful research
results, entry of new competitors and products, adverse federal, state and local
government regulation, inadequate capital, unexpected costs and operating
deficits, increases in general and administrative costs, termination of
contracts or agreements, technological obsolescence of the Company's products,
technical problems with the Company's research and products, price increases for
supplies and components, litigation and administrative proceedings involving the
Company, the possible acquisition of new businesses or technologies that result
in operating losses or that do not perform as anticipated, unanticipated losses,
the possible fluctuation and volatility of the Company's operating results,
financial condition and stock price, losses incurred in litigating and settling
cases, dilution in the Company's ownership of its business, adverse publicity
and news coverage, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and research
scientists, changes in interest rates, inflationary factors, and other specific
risks. We currently have no commercial products intended to diagnose, treat,
prevent or cure any disease. The statements contained in this press release
regarding our on going research and development and the results attained by us
to-date have not been evaluated by the Food and Drug Administration. There can
be no assurance that further research and development, and /or whether clinical
trial results, if any, will validate and support the results of our preliminary
research and studies. Further, there can be no assurance that the necessary
regulatory approvals will be obtained or that HepaLife will be able to develop
commercially viable products on the basis of its technologies. In addition,
other factors that could cause actual results to differ materially are discussed
in the Company's most recent Form 10-Q and Form 10-K filings with the Securities
and Exchange Commission. These reports and filings may be inspected and copied
at the Public Reference Room maintained by the U.S. Securities & Exchange
Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain
information about operation of the Public Reference Room by calling the U.S.
Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities &
Exchange Commission also maintains an Internet site that contains reports, proxy
and information statements, and other information regarding issuers that file
electronically with the U.S. Securities & Exchange Commission at
http://www.sec.gov. The Company undertakes no obligation to publicly release the
results of any revisions to these forward looking statements that may be made to
reflect the events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.

SOURCE: HepaLife Technologies, Inc.



CONTACT: HepaLife Technologies, Inc.Mr. Frank Menzler, 800-518-4879President




Copyright Business Wire 2008

-0-




KEYWORD: United States

North America

California

Massachusetts

INDUSTRY KEYWORD: Health

Biotechnology

Medical Devices

Pharmaceutical

Other Health

Research

Other Science

Science

SUBJECT CODE: Conference

Product/Service

Source: Comtext Market News
Go to Previous message | Go to Next message | Back to Messages
ASCII (ASCII)Greek (ISO-8859-7)Greek (Windows-1253)Latin-10 (ISO-8859-16)Latin-3 (ISO-8859-3)Latin-6 (ISO-8859-10)Latin-7 (ISO-8859-13)Latin-8 (ISO-8859-14)Latin-9 (ISO-8859-15)W. European (850)W. European (CP858)W. European (HPROMAN8)W. European (MACROMAN8)W. European (Windows-1252)Armenia (ARMSCII-8)Baltic Rim (ISO-8859-4)Baltic Rim (WINDOWS-1257)Cyrillic (866)Cyrillic (ISO-8859-5)Cyrillic (KOI8-R)Cyrillic (KOI8-RU)Cyrillic (KOI8-T)Cyrillic (KOI8-U)Cyrillic (WINDOWS-1251)Latin-2 (852)Latin-2 (ISO-8859-2)Latin-2 (WINDOWS-1250)Turkish (ISO-8859-9)Turkish (WINDOWS-1254)Arabic (ISO-8859-6, ASMO-708)Arabic (WINDOWS-1256)Hebrew (856)Hebrew (862)Hebrew (WINDOWS-1255)Chinese Simplified (GB-2312-80)Chinese Simplified (GB18030)Chinese Simplified (HZ-GB-2312)Chinese Simplified (ISO-2022-CN)Chinese Simplified (WINDOWS-936)Chinese Trad.-Hong Kong (BIG5-HKSCS)Chinese Traditional (BIG5)Chinese Traditional (EUC-TW)Japanese (SHIFT_JIS)Japanese (EUC-JP)Japanese (ISO-2022-JP)Korean (ISO-2022-KR)Korean (EUC-KR)Thai (TIS-620-2533)Thai (WINDOWS-874)Vietnamese (TCVN-5712)Vietnamese (VISCII)Vietnamese (WINDOWS-1258)Unicode (UTF-7)Unicode (UTF-8)Unicode (UTF-16)Unicode (UTF-32)
| Full Headers
Search Mail